Sign in to view content

RO-104, a Novel Trispecific Antibody, Significantly Reduces Lesion Area and Vascular Leakage in a Laser-Induced Nonhuman Primate CNV Model

Harit K. Bhatt, MD, MBA, FASRS, FACS

Video
Published 2025

Related

Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2022
Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Caroline Baumal, MD, FASRS
Annual Meeting Talks
2021
Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Caroline Baumal, MD, FASRS
Updates from the Field
2021

Category: AMD-Neovascular

See more